- Visibility 398 Views
- Downloads 666 Downloads
- Permissions
- DOI 10.18231/j.ijcaap.2025.018
-
CrossMark
Pramipexole for symptoms of depression in patients with Parkinsonism/ Parkinson’s disease
- Author Details:
-
Amandeep Singh
-
Prithpal S Matreja *
-
Harmeet Singh
-
Ashwani K Gupta
-
Jaspreet Kaur
Amandeep Singh
Prithpal S Matreja *
Ashwani K Gupta
In patients with PD, depressive symptoms are seen in more than one-third of cases for which patients are prescribed conventional antidepressant drugs - NSRIs (noradrenaline serotonin reuptake inhibitors), SSRIs (selective serotonin reuptake inhibitors) and tricyclic antidepressants (TCAs). Pramipexole is a non-ergoline derivative dopamine agonist used for the treatment of Parkinsonism/Parkinson's disease (PD) as well as for treatment moderate to severe idiopathic Restless Legs Syndrome (RLS), has also been found useful and rather superior to some of these conventional anti-depressant drugs for improvement in the symptoms of depression in patients with PD. The available data from various studies suggests that pramipexole may be used as an alternative to conventional antidepressant drugs in patients with symptoms of depression in PD. This article highlights role of pramipexole in depression.
Keywords: Parkinson’s disease/Parkinsonism, Pramipexole, Depression.
References
- Reijnders JSAM, Ehrt U, Weber WEJ, Aarsland D, Leentjens AFG. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord. 2008 Jan 30;23(2):183-9 Singh et al. / IP International Journal of Comprehensive and Advanced Pharmacology 2025;10(2):119–121 121
- Barone P, Goetz CG, Houben JJ, Koester J, Leentjens AF, Poewe W, et al. PRODEST– Depressive symptoms in Parkinson’s disease: Effect of antidepressant treatment on symptom items of depression. 60th AAN Annual Meeting. Chicago, IL, USA, 2008: P05.145.
- Braak H, Braak E. Pathoanatomy of Parkinson’s disease. J Neurol. 2000;247 Suppl 2:II 3–10.
- Mayberg HS, Solomon DH. Depression in Parkinson's disease: a biochemical and organic viewpoint. Adv Neurol. 1995;65:49–60.
- Shafer RA, Levant B. The D3 dopamine receptor in cellular and organismal function. Psychopharmacology (Berl). 1998;135(1):1– 16
- Lieberman A. Depression in Parkinson’s disease – a review. Acta Neurol Scand. 2006;113(1):1–8.
- Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain. 2005 Jun;128(Pt 6):1314-22.
- Ishibashi K, Ishii K, Oda K, Mizusawa H, Ishiwata K. Binding of pramipexole to extrastriatal dopamine D2/D3 receptors in the human brain: a positron emission tomography study using 11C-FLB
- PLoS One. 2011;6(3):e17723.
- Barone P. Treatment of depressive symptoms in Parkinson's disease. Eur J Neurol. 2011;18 Suppl 1:11–5.
- Kano O, Ikeda K, Kiyozuka T, Iwamoto K, Ito H, Kawase Y, et al. Beneficial effect of pramipexole for motor function and depression in Parkinson's disease. Neuropsychiatr Dis Treat. 2008;4(4):707–10.
- Yasui N, Sekiguchi K, Hamaguchi H, Kanda F. The effect of pramipexole on depressive symptoms in Parkinson's disease. Kobe J Med Sci. 2011;56(5):E214–9.
- Barone P, Scarzella L, Marconi R, Antonini A, Morgante L, Bracco F, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol. 2006;253(5):601–7.
- Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(6):573–80.